Litcius/Paper detail

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Linong Ji, Leili Gao, Haibo Xue, Junhang Tian, Kun Wang, Hongwei� Jiang, Chun‐Jui Huang, Qiufang Lian, Mingxia Yuan, Ge Gao, Yibing Lu, Jie Han, Wenyan Fu, Haifang Wang, Yawei Zhang, Xiaoguang Shi, Binhong Wen, Bimin Shi, Wen Hu, Tonglan Guo, Ying Xing, Ya Li, Qingju Li, Qing Zheng, Ming Yang, Jing Ning, Mengying Guo, Yao Li, Hongbo Pan

2025The Lancet Diabetes & Endocrinology22 citationsDOI

Topics & Concepts

MedicinePlaceboOverweightAgonistObesityGlucagon-like peptide 1 receptorInternal medicineClinical trialLiraglutideDouble blindDiabetes mellitusPhysical therapyType 2 diabetesAlternative medicineEndocrinologyReceptorPathologyDiabetes Treatment and ManagementPharmacology and Obesity TreatmentBariatric Surgery and Outcomes